Clinical trial · Interventional
Spatially Fractionated Radiotherapy for Tumor Treatment
Spatially Fractionated Radiotherapy for Bulky or Refractory Solid Tumors: Efficacy and Toxicity
NCT07774819CI-TRIAL-00122713recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the efficacy and toxicity of spatially fractionated radiotherapy in the treatment of tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radiotherapy-Induced Immune Priming | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| spatially fractionated radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SFRT arm
- description
- Adding spatially fractionated radiotherapy (SFRT) to standard-of-care treatment.
- interventionNames
- Radiation: spatially fractionated radiotherapy
Primary outcomes (2)
- measure
- Number and percentage of participants with treatment-related grade ≥3 adverse events as assessed by CTCAE v5.0
- timeFrame
- From initiation of spatially fractionated radiation therapy through 90 days after completion of radiotherapy
- description
- Safety will be assessed by the incidence of treatment-related adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The number and percentage of participants experiencing at least one treatment-related grade ≥3 adverse event during the specified assessment period will be reported. Treatment-related serious adverse events and grade 5 adverse events will also be summarized descriptively.Whether this study can be successfully executed and implemented.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a bulky solid tumor with a maximum diameter \>4 cm or a refractory solid tumor. Exclusion Criteria: * Tumors involving hollow viscera that are considered to have a clinically significant risk of bleeding or perforation. * Patients with impaired consciousness or who are unable to care for themselves.
References
Publications (0)
Data not yet available
No reference posted for this study.